Abstract
Background
Distal extrahepatic bile duct (EHBD) cancer is highly recurrent. More than 50% of patients suffer from disease relapse after curative resection. Some patients present with oligo‐recurrence which could be a single loco‐regional mass or lesions limited to a single solid organ. The aim of this study was to examine the effect of local control (surgical resection or radiofrequency ablation) on survival outcomes in patients with oligo‐recurrent distal EHBD cancer.
Methods
Data of 1219 patients who underwent surgery for distal EHBD cancer from 2000 to 2018 were retrospectively reviewed. Clinicopathological characteristics and survival outcomes of patients with recurrence were investigated. Post‐recurrence survival (PRS) was analyzed according to modalities of re‐treatment (local treatment or systemic therapy alone).
Results
Among 654 patients with recurrence, 90 patients who had oligo‐recurrence showed better recurrence‐free and overall survival than patients with non‐oligo‐recurrent disease. Lymph node ratio and perineural invasion at initial pathology, timing of recurrence, and platelet‐to‐lymphocyte ratio at recurrence were independent risk factors for PRS in the oligo‐recurrent group. Patients with local treatment for oligo‐recurrence had better 3‐ and 5‐year PRS than those with systemic treatment alone (38.3% vs. 14.1%, p = 0.04; 28.3% vs. 7.1%, p = 0.04, respectively). Recurrence within 24 months after initial surgery was the only significant factor for PRS in the local treatment group.
Conclusion
In patients with oligo‐recurrence after resection of distal EHBD cancer, post‐recurrence local treatment could improve survival outcomes, particularly for those with recurrence more than 2 years after initial resection.
Keywords: bile duct cancer, cholangiocarcinoma, oligo‐recurrence, recurrence, survival
Post‐recurrence survival according to modalities of post‐recurrence treatment in patients with oligo‐recurrence.
Lay summary
Distal bile duct cancer is highly recurrent, and chemotherapy remains the standard for recurrent cancer. However, there are some patients who present with a few lesions in a limited area, which can be considered as ‘oligo‐recurrence’. Oligo‐recurrent tumors can be removed by local treatment such as re‐operation or local ablative therapy. In the present study, we investigated the impact of local treatment on survival of patients with oligo‐recurrent bile duct cancer.
Precis
After resection of distal bile duct cancer, some patients present with oligo‐recurrent tumors, having potential for local treatment with curative intent. The present study identified that post‐recurrence local treatment improved survival in patients with oligo‐recurrent distal cholangicarcinoma, particularly for those with disease‐free interval of more than 2 years.
1. INTRODUCTION
Bile duct cancers, also known as cholangiocarcinomas, are highly lethal malignancies usually diagnosed at locally advanced stage with a low chance of curative surgery. Anatomically, distal extrahepatic bile duct (EHBD) cancer includes cholangiocarcinomas arising from the level of the cystic duct to distal common bile duct (CBD). 1 EHBD cancers are also classified as mid and distal common bile duct (CBD) cancers. Surgical management of distal EHBD cancer can be segmental bile duct resection or pancreatoduodenectomy. 2 Prognosis after surgical resection has been improved, with a recent study reporting that the 5‐year overall survival rate after R0 resection is 44%. 3
It has been previously reported that more than half of patients suffer from recurrences after surgery. 4 The pattern of recurrence could be either localized or diffused. The number and location of recurrent tumors can also vary according to previous studies. 5 , 6 Niibe et al have proposed the notion of oligo‐recurrence (a state of ≤5 metastatic or recurrent lesions after control of primary tumors). 7 Our institution has previously explored oncologic benefits of re‐resection in recurrent cholangiocarcinoma and found that survival could be improved by surgery of loco‐regional oligo‐recurrent tumors. 6 Some studies have reported the effectiveness of surgical interventions for recurrent biliary tract cancer. 8 , 9 , 10 , 11 However, most of these studies included other types of biliary tract cancers as well as distal EHBD cancer and were also based on limited numbers of patients.
As of now, only limited data are available on which patient might obtain survival benefit by local treatment of recurrent distal EHBD cancer and when to perform it. Therefore, the objectives of this study were: (1) to determine characteristics of patients with oligo‐recurrent distal EHBD cancer using a large cohort from bi‐institutional data; and (2) to investigate the effect and optimal timing of local re‐interventions for oligo‐recurrent tumors.
2. MATERIALS AND METHODS
2.1. Patient database
All consecutive patients with resected distal CBD cancer between January 2000 and December 2018 in Samsung Medical Center and Severance Hospital were eligible for this study. Data of 1219 patients were collected. All patients underwent either bile duct resection or pancreatoduodenectomy with regional lymph node dissection. Among them, patients who had recurrent disease during follow‐up were included in the analysis. Demographic characteristics and clinicopathological variables at initial surgery and at recurrence were retrospectively reviewed. Laboratory data included carbohydrate antigen 19–9 (CA 19–9), inflammatory markers such as neutrophil‐to‐lymphocyte ratio (NLR), and platelet‐to‐lymphocyte ratio (PLR). Pathology report included the size and differentiation of tumor, numbers of harvested and metastatic lymph nodes (LNs), lymphovascular invasion (LVI) or perineural invasion (PNI), and R status indicating curative resection. Lymph node ratio (LNR) was calculated as the number of metastatic LNs divided by the number of harvested LNs. This study was approved by the Institutional Review Boards of Samsung Medical Center (SMC 2021–07‐027) and Severance Hospital, Yonsei University College of Medicine (4–2022‐0929).
2.2. Diagnosis of recurrence and post‐recurrence treatment
Recurrence was diagnosed when patients presented with elevated CA 19–9 and suspicious tumors identified from imaging studies such as computed tomography (CT) scans or had pathologically proved as adenocarcinoma from biopsy. Positron emission tomography (PET) scan was additionally performed if the diagnosis was ambiguous. We defined oligo‐recurrence as a single localized recurrent lesion or no more than five multiple lesions in a single organ, which could be removed by local ablation or surgical resection. Post‐recurrence treatment plan was established considering characteristics of recurrence and general condition of a patient. For patients with oligo‐recurrence, re‐resection or radiofrequency ablation (RFA) was recommended. When patients had unbearable condition for general anesthesia or refused local treatment, additional chemotherapy or observation was considered.
2.3. Statistical analysis
Recurrence‐free survival (RFS) was calculated as the time interval between the date of operation and the date when recurrent tumors were identified in imaging studies. Overall survival (OS) was defined as the time from initial surgery to death from any causes. Post‐recurrence survival (PRS) was defined as the period from the date of recurrence to death.
Comparisons of peri‐operative clinical variables, intraoperative findings, postoperative outcomes, and pathological features were conducted using Student's t‐test and Chi‐squared test. Kaplan–Meier curves with log‐rank tests were used to compare survivals between patients with oligo‐recurrence and diffuse recurrence. Univariable and multivariable logistic regression models were used to identify factors associated with survival. Hazard ratios (HRs) were reported with 95% confidence intervals (CIs). The z‐test was performed to compare the survival probability at a specific time between patients. Variables with p‐values <0.05 were regarded as statistically significant. All statistical analyses were performed using IBM SPSS version 26 (SPSS Inc.) and SAS version 9.4 (SAS Institute Inc).
3. RESULTS
Among a total of 1219 patients with resected distal CBD cancer, 135 patients were lost to follow‐up and 654 (53.7%) patients showed recurrent cancer. The median time to recurrence was 13.0 months. Among the patients with recurrence, the number of patients with oligo‐recurrence was 90 (13.8%). Table 1 shows comparisons of clinicopathological characteristics between patients with oligo‐recurrence and diffuse recurrence. Mean body mass index (BMI) at initial operation was higher in patients with oligo‐recurrence (25.0 kg/m2 vs. 23.3 kg/m2, p = 0.011). Regarding pathological features, the numbers of both harvested and metastatic LNs were higher in the diffuse recurrence group (15.5 vs. 17.8, p = 0.047; 0.7 vs. 1.3, p = 0.004). There were more patients with LNR >0.1 in the diffuse recurrence group (24.3% vs. 15.6%, p = 0.045). LVI was more frequent in patients with diffuse recurrence than in those with oligo‐recurrence (53.7% vs. 37.9%, p = 0.017). In survival analysis, RFS and OS were significantly higher in the oligo‐recurrence group than in the diffuse recurrence group (median RFS: 17 months vs. 12 months, p = 0.001; median OS: 41 months vs. 23 months, p < 0.001) (Figure 1).
TABLE 1.
Comparisons of clinicopathological characteristics between the oligo‐recurrence group and the diffuse recurrence group at initial operation.
| Variables | Oligo‐recurrence group (n = 90) | Diffuse recurrence group (n = 564) | p |
|---|---|---|---|
| Age (year), mean | 64.7 (±8.5) | 66.0 (±8.7) | 0.984 |
| Sex, male | 55 (61.1%) | 372 (66.0%) | 0.370 |
| BMI (kg/m2), mean | 25.0 (±14.3) | 23.3 (±3.5) | 0.011 |
| Sx._Abdominal pain, yes | 19 (21.1%) | 10 (30.1%) | 0.079 |
| Sx._Jaundice, yes | 52 (57.8%) | 323 (57.3%) | 0.928 |
| Pre‐op CA19‐9 (U/mL), mean | 914.0 (±6909.7) | 814.7 (±5176.6) | 0.628 |
| Elevated CA19‐9, yes | 46 (51.1%) | 326 (59.4%) | 0.140 |
| Initial serum total bilirubin (mg/dL), mean | 6.7 (±6.5) | 7.6 (±7.6) | 0.053 |
| Pre‐op serum total bilirubin (mg/dL), mean | 3.1 (±3.5) | 3.3 (±3.5) | 0.660 |
| NLR, mean | 2.8 (±2.1) | 2.8 (±3.4) | 0.994 |
| PLR, mean | 195.8 (±97.9) | 180.0 (±96.2) | 0.153 |
| ASA score | 0.966 | ||
| I–II | 55 (78.6%) | 307 (79.7%) | |
| III–IV | 15 (21.4%) | 79 (20.4%) | |
| Operation type | 0.155 | ||
| BDR | 28 (31.1%) | 136 (24.1%) | |
| PD | 62 (68.9%) | 428 (75.9%) | |
| Combined vascular resection | 2 (2.2%) | 16 (2.8%) | 0.741 |
| Tumor size (cm), mean | 2.5 (±1.1) | 2.8 (±4.4) | 0.536 |
| Tumor differentiation | 0.429 | ||
| WD/MD | 66 (76.7%) | 383 (72.7%) | |
| PD/Undifferentiated | 20 (23.3%) | 144 (27.3%) | |
| LN metastasis, yes | 29 (32.2%) | 237 (42.5%) | 0.067 |
| No. of harvested LNs, mean | 15.5 (± 9.3) | 17.8 (±9.9) | 0.047 |
| No. of metastatic LNs, mean | 0.7 (± 1.5) | 1.3 (±2.4) | 0.004 |
| LN ratio >0.1 | 14 (15.6%) | 141 (25.3%) | 0.045 |
| LVI, yes | 25 (37.9%) | 208 (53.7%) | 0.017 |
| PNI, yes | 71 (85.5%) | 428 (88.4%) | 0.454 |
| R0 resection | 79 (87.8%) | 497 (88.1%) | 0.926 |
| Major complication, yes | 19 (21.1%) | 102 (18.1%) | 0.492 |
| Adjuvant therapy, yes | 42 (46.7%) | 218 (38.9%) | 0.164 |
| Median recurrence‐free survival, months | 17.0 | 12.0 | 0.001 |
| Median overall survival, months | 41.0 | 23.0 | <0.001 |
Abbreviations: ASA, American Society of Anesthesiology; BDR, bile duct resection; BMI, body mass index; CA 19–9, carbohydrate antigen 19–9; LN, lymph node; LVI, lymphovascular invasion; MD, moderately differentiated; NLR, neutrophil‐to‐lymphocyte ratio; No., the number; PD (Operation type), pancreatoduodenectomy; PD (Tumor differentiation), poorly differentiated; PLR, platelet‐to‐lymphocyte ratio; PNI, perineural invasion; Pre‐op., preoperative; Sx., symptom; WD, well differentiated.
FIGURE 1.
(A) Recurrence‐free survival and (B) Overall survival of patients with oligo‐recurrence and diffuse recurrence.
The most common site of oligo‐recurrence was the liver, followed by intra‐abdominal mass, remnant bile duct, and lung (Table 2). In the oligo‐recurrence group, 44 patients underwent post‐recurrence local treatment with or without additional systemic adjuvant therapy, 27 patients had systemic treatment alone, and 18 patients had no further treatment.
TABLE 2.
Oligo‐recurrence sites and types of post‐recurrence treatment (n = 90).
| Recur site | Liver (n = 56) | Remnant bile duct (n = 11) | Intra‐abdominal mass (n = 18) | Lung (n = 5) |
|---|---|---|---|---|
| Local tx. | ||||
| Re‐op. (n = 29) | ||||
| Without systemic tx. | 5 | 3 | 6 | 4 |
| With systemic tx. | 3 | 4 | 4 | 0 |
| RFA (n = 15) | ||||
| Without systemic tx. | Without systemic tx. | — | — | — |
| With systemic tx. | 7 | — | — | — |
| Systemic tx. Only (n = 27) | 18 | 2 | 7 | 0 |
| No tx. (n = 18) | 15 | 2 | 1 | 1 |
Abbreviations: Re‐op., re‐operation; RFA, radiofrequency ablation; Tx., treatment.
Survival rates at 2, 3, and 5 years after recurrence were compared among patients with oligo‐recurrence (Figure 2). Three‐year and 5‐year PRS rates were significantly different between patients with local treatment and those with systemic treatment alone (3‐year PRS: 38.3% vs. 14.1%, p = 0.043; 5‐year PRS: 28.3% vs. 7.1%, p = 0.049). Risk factor analysis was performed to investigate factors related to PRS in the oligo‐recurrence group (Table 3). In multivariable analysis, LNR and PNI at initial pathology were statistically significant risk factors (HR: 15.037, 95% CI: 1.037–218.089, p = 0.047; HR: 4.287, 95% CI: 1.639–11.210, p = 0.003, respectively). Disease‐free interval of less than 24 months was associated with poor PRS (HR: 2.477, 95% CI: 1.312–4.674, p = 0.005). Among variables at the time of recurrence, PLR was an independent factor (HR: 1.007, 95% CI: 1.002–1.011, p = 0.006).
FIGURE 2.
Post‐recurrence survival according to modalities of post‐recurrence treatment in patients with oligo‐recurrence.
TABLE 3.
Risk factor analysis for post‐recurrence survival in patients with oligo‐recurrence (n = 90).
| Variable | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | |
| Clinicopathological factors at initial operation | ||||||
| Age at operation | 1.020 | 0.991–1.049 | 0.172 | |||
| Sex, female (ref. male) | 1.176 | 0.692–1.998 | 0.548 | |||
| BMI | 0.903 | 0.829–0.983 | 0.019 | 0.957 | 0.869–1.055 | 0.378 |
| Sx._Abdominal pain, yes | 0.930 | 0.492–1.756 | 0.822 | |||
| Sx._Jaundice, yes | 1.054 | 0.625–1.778 | 0.843 | |||
| Elevated pre‐op. CA19‐9 | 1.185 | 0.707–1.988 | 0.520 | |||
| Initial serum total bilirubin | 0.975 | 0.934–1.018 | 0.247 | |||
| Pre‐op. serum total bilirubin | 0.941 | 0.846–1.047 | 0.266 | |||
| Pre‐op. NLR | 0.992 | 0.893–1.102 | 0.876 | |||
| Pre‐op. PLR | 1.000 | 0.998–1.003 | 0.741 | |||
| Operation type, PD (ref. BDR) | 0.709 | 0.400–1.254 | 0.237 | |||
| Tumor size | 0.952 | 0.782–1.160 | 0.628 | |||
| Tumor differentiation, PD (ref. WD/MD) | 1.372 | 0.776–2.424 | 0.277 | |||
| LN metastasis, yes | 1.400 | 0.823–2.381 | 0.215 | |||
| LN ratio | 11.001 | 1.384–87.450 | 0.023 | 15.037 | 1.037–218.089 | 0.047 |
| LVI, yes | 1.136 | 0.603–2.142 | 0.693 | |||
| PNI, yes | 1.968 | 0.882–4.393 | 0.098 | 4.287 | 1.639–11.210 | 0.003 |
| R0 resection | 1.308 | 0.659–2.594 | 0.443 | |||
| Adjuvant therapy, yes | 0.813 | 0.487–1.357 | 0.428 | |||
| Disease‐free interval <24 months (n = 55) | 1.827 | 1.038–3.215 | 0.037 | 2.477 | 1.312–4.674 | 0.005 |
| Clinical factors at the timing of recurrence | ||||||
| Age at recur | 1.016 | 0.988–1.045 | 0.271 | |||
| BMI at recur | 0.946 | 0.864–1.035 | 0.228 | |||
| Elevated CA 19–9 at recur | 1.396 | 0.821–2.374 | 0.218 | |||
| Serum total bilirubin at recur | 0.605 | 0.231–1.586 | 0.307 | |||
| NLR at recur | 1.120 | 0.969–1.294 | 0.126 | |||
| PLR at recur | 1.007 | 1.003–1.011 | 0.001 | 1.007 | 1.002–1.011 | 0.006 |
| Recur site, liver (ref. others) | 0.997 | 0.585–1.700 | 0.993 | |||
| Adjuvant chemotherapy after recur | 0.665 | 0.399–1.109 | 0.118 | |||
Abbreviations: BDR, bile duct resection; BMI, body mass index; CA 19–9, carbohydrate antigen 19–9; LN, lymph node; LVI, lymphovascular invasion; MD, moderately differentiated; NLR, neutrophil‐to‐lymphocyte ratio; PD (Op type), pancreatoduodenectomy; PD (Tumor differentiation), poorly differentiated; PLR, platelet‐to‐lymphocyte ratio; PNI, perineural invasion; Pre‐op., preoperative; Sx., symptom; WD, well differentiated.
In the analysis for identifying relevant factors for PRS in the patients undergoing post‐recurrence local treatment, the only statistically significant factor was disease‐free interval (HR: 3.045, 95% CI: 1.042–8.895, p = 0.042) (Table 4). The PRS was compared between patient groups stratified by the disease‐free interval of 12, 24, and 36 months (Figure 3). The PRS differed significantly when the patients were divided over the disease‐free interval of 24 months (p = 0.024).
TABLE 4.
Risk factor analysis for post‐recurrence survival in patients with local treatment for oligo‐recurrence (n = 44).
| Variable | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | |
| Clinicopathological factors at initial operation | ||||||
| Age at operation | 1.021 | 0.983–1.061 | 0.289 | |||
| Sex, female (ref. male) | 1.114 | 0.505–2.461 | 0.789 | |||
| BMI | 0.906 | 0.794–1.034 | 0.142 | |||
| Sx._Abdominal pain, yes | 0.779 | 0.310–1.955 | 0.595 | |||
| Sx._Jaundice, yes | 1.033 | 0.463–2.306 | 0.937 | |||
| Elevate pre‐op. CA19‐9 | 1.177 | 0.540–2.569 | 0.682 | |||
| Initial serum total bilirubin | 0.976 | 0.918–1.036 | 0.420 | |||
| Pre‐op. serum total bilirubin | 0.962 | 0.835–1.107 | 0.587 | |||
| Pre‐op. NLR | 0.986 | 0.855–1.136 | 0.843 | |||
| Pre‐op. PLR | 1.000 | 0.996–1.004 | 0.969 | |||
| Op type, PD (ref. BDR) | 0.830 | 0.320–2.148 | 0.700 | |||
| Tumor size | 1.005 | 0.793–1.274 | 0.964 | |||
| Tumor differentiation, PD (ref. WD/MD) | 1.627 | 0.680–3.890 | 0.274 | |||
| LN metastasis, yes | 1.308 | 0.574–2.979 | 0.522 | |||
| LN ratio | 132.23 | 0.042–419,432 | 0.235 | |||
| LVI, yes | 1.111 | 0.427–2.891 | 0.829 | |||
| PNI, yes | 1.588 | 0.533–4.730 | 0.406 | |||
| R0 resection | 1.433 | 0.484–4.240 | 0.516 | |||
| Adjuvant therapy, yes | 0.698 | 0.311–1.564 | 0.382 | |||
| Disease‐free interval <24 months (n = 30) | 2.871 | 1.079–7.637 | 0.035 | 3.045 | 1.042–8.895 | 0.042 |
| Clinical factors at the timing of recurrence | ||||||
| Age at recur | 1.015 | 0.976–1.054 | 0.459 | |||
| BMI at recur | 0.977 | 0.863–1.106 | 0.715 | |||
| Elevated CA 19–9 at recur | 1.950 | 0.881–4.319 | 0.100 | |||
| Serum total bilirubin at recur | 0.559 | 0.164–1.903 | 0.352 | |||
| NLR at recur | 1.075 | 0.817–1.414 | 0.605 | |||
| PLR at recur | 1.007 | 1.000–1.015 | 0.060 | 1.006 | 0.997–1.015 | 0.192 |
| Adjuvant (systemic) treatment after recur | 0.706 | 0.326–1.533 | 0.379 |
Abbreviations: BDR, bile duct resection; BMI, body mass index; CA 19–9, carbohydrate antigen 19–9; LN, lymph node; LVI, lymphovascular invasion; MD, moderately differentiated; NLR, neutrophil‐to‐lymphocyte ratio; PD (Op type), pancreatoduodenectomy; PD (Tumor differentiation), poorly differentiated; PLR, platelet‐to‐lymphocyte ratio; PNI, perineural invasion; Pre‐op., preoperative; Sx., symptom; WD, well differentiated.
FIGURE 3.
Post‐recurrence survival in patients with local treatment for oligo‐recurrence stratified by disease‐free interval of (A) 12 months, (B) 24 months, and (C) 36 months.
4. DISCUSSION
Cholangiocarcinomas have an aggressive behavior. Relapses are common even after curative resection. Patients with recurrent disease have been treated in a palliative manner, usually with systemic chemotherapy or supportive care only. 12 In recent years, a number of studies have reported that local control of recurrent tumors such as re‐resection or ablative therapy might improve survival outcomes. 8 , 9 , 10 , 11 However, most of the previous studies included only intrahepatic cholangiocarcinoma. Only a limited number of studies have been conducted on distal CBD cancer. Considering that biological, clinicopathological features, and prognosis vary among anatomically classified cholangiocarcinomas, 13 an in‐depth investigation on recurrent distal CBD cancer as a single disease entity is necessary.
Regarding oligo‐recurrence, there have been previous reports on isolated recurrence of biliary tract or pancreatic cancer after resection, even before the concept was proposed in 2010. 7 In terms of pancreatic cancer, it is known that approximately 30% of patients with local recurrence have isolated recurrence. 14 According to a recent meta‐analysis, 15 re‐resection of isolated recurrent pancreatic cancer could offer survival benefit. Furthermore, it has been reported that among patients with potentially curative recurrent lesions, those with a single pulmonary recurrence with a longer disease‐free interval are more likely to have a better chance of survival. 16 Similarly, there are a few case series from high‐volume centers reporting reoperation for recurrent distal bile duct cancer, 6 , 8 , 10 with the authors arguing the feasibility of resecting recurrent tumors. However, little is known about the selection of eligible patients and the proper timing of re‐treatment. Therefore, our study placed more emphasis on patients with oligo‐recurrence of distal CBD cancer, aiming to explore any distinct features of them and to investigate proper candidates who might benefit from post‐recurrence local treatment.
Some risk factors related to survival after resection of distal CBD cancer have been reported, including tumor differentiation, LN metastasis, resection margin, PNI, and depth of invasion. 17 In the present study, patients with oligo‐recurrence had better survival outcomes with lower LNR and less LVI than those with non‐oligo‐recurrence. In the oligo‐recurrent group, LNR, PNI at initial pathology, and PLR at recurrence were associated with PRS. It is noticeable that LNR, rather than the presence of LNM itself, was an independent prognostic factor, which is consistent with the result of a former study. 18 Since LNR reflects the number of retrieved LNs as well as the number of metastatic LNs, the number of LN yielded could be influential. A recent study has suggested that at least five nodes should be examined to apply the eighth edition of the American Joint Committee on Cancer (AJCC) system with accuracy. 19 In order to utilize LNR as a prognosticator, a further study on the appropriate number of lymph node yield and the optimal cut‐off value is necessary.
Inflammatory markers have recently emerged as potential prognostic factors for several malignancies including biliary tract cancers. 20 The possible relationship between inflammatory markers and oncologic outcomes arises from the role of chronic inflammation in developing cancers. According to some previous studies, systemic inflammation could be either cause or effect of malignancy. 21 , 22 Regardless, inappropriately activated immune system might result in increases of circulating neutrophil and platelet. Hence, NLR and PLR could reflect biological activity of tumor. Kitano et al have reported that elevated preoperative PLR is associated with poor survival outcomes in patients with resected extrahepatic cholangiocarcinoma. 23 In the present study, PLR at recurrence, rather than preoperative value, was an independent risk factor for PRS. It might suggest that PLR at recurrence reflects the nature of recurrent tumor, not primarily resected tumor, and affects survival after recurrence. Many other inflammatory and immune‐nutritional markers such as lymphocyte‐to‐monocyte ratio, Glasgow prognostic score, and prognostic nutritional index are under investigation. Considering that data of these markers are readily available from perioperative blood tests, additional research on clinical implication and prognostic value of the abovementioned markers should be undertaken.
With regard to the timing of post‐recurrence treatment, based on disease‐free interval of 24 months, PRS was found to be significantly different among patients with local treatment. Furthermore, the only predictive factor for PRS in this group was RFS of 24 months. This result is somewhat consistent with a study by Takahashi et al, which reported that survival after re‐resection of recurrent biliary tract cancer was better in patients with disease‐free interval of two or more years. 10 This can be also associated with the issue of early or late recurrence. In this respect, patients with late recurrence might get a better chance of survival by post‐recurrence treatment. A few studies have investigated early recurrence of distal CBD cancer after surgery. One of them has defined early recurrence as disease relapse within 1 year after curative resection, and reported that lymphatic invasion is a significant prognosticator for early recurrence. 24 Another study has found that older age, elevated serum CA 19–9, and PNI are associated with recurrence of EHBD cancer within 6 months of surgery. 25
To select patients who have a high possibility of prolonged survival by post‐recurrence local treatment, further work is needed to understand implications of the timing of recurrence and to explore risk factors related to better outcomes of recurrent distal CBD cancer.
This study has a number of potential limitations that need to be considered. First, significant biases might have affected results owing to the retrospective design. Among all patients who underwent surgery, some patients who were lost to follow‐up without information on recurrence were excluded. Also, due to its nature of multi‐center study, there existed a few differences in detail between institutions regarding post‐operative patient follow‐up and decision on post‐recurrence treatment. As for patients with oligo‐recurrence, decision on local treatment was shared with patients considering their overall conditions. However, no objective indicator was available for determining if a patient could tolerate local therapy. There were no criteria for selecting modalities of local treatment between RFA and surgical resection. This led to unsolved issue regarding which modalities would have affected the PRS in the patients with local treatment. Despite all these limitations, we obtained comprehensive results for understanding oligo‐recurrence of distal EHBD cancer and the effect of post‐recurrence local treatment by analyzing a large cohort from various angles. Accordingly, the present study demonstrates that local therapy for late‐onset oligo‐recurrent distal CBD cancer might offer a patient a better chance of survival on a long‐term basis. Further prospective studies are needed to verify appropriate candidates and the feasibility of local treatment for recurred distal CBD cancer.
AUTHOR CONTRIBUTIONS
So Jeong Yoon: Conceptualization (lead); data curation (lead); formal analysis (lead); writing – original draft (lead); writing – review and editing (lead). Seung Soo Hong: Conceptualization (lead); data curation (lead); formal analysis (lead); writing – original draft (lead); writing – review and editing (lead). Min Jae Gwon: Formal analysis (equal); writing – original draft (equal); writing – review and editing (equal). Sang Hyun Shin: Conceptualization (equal); data curation (equal); formal analysis (equal); writing – original draft (equal); writing – review and editing (equal). Jin Seok Heo: Conceptualization (equal); data curation (equal); formal analysis (equal); writing – original draft (equal); writing – review and editing (equal). Chang Moo Kang: Conceptualization (equal); data curation (equal); formal analysis (equal); writing – review and editing (equal). Kyung Sik Kim: Conceptualization (equal); data curation (equal); formal analysis (equal); writing – review and editing (equal). Ho Kyoung Hwang: Conceptualization (lead); data curation (lead); formal analysis (lead); writing – original draft (lead); writing – review and editing (lead). In Woong Han: Conceptualization (lead); data curation (lead); formal analysis (lead); writing – original draft (lead); writing – review and editing (lead).
FUNDING INFORMATION
This work was supported by the National Research Foundation of Korea grant funded by the Korea government (Ministry of Science and ICT) (NRF‐2022M3H4A1A01012816).
CONFLICT OF INTEREST STATEMENT
The authors have no conflicts of interest relevant to this study to disclose.
Yoon SJ, Hong SS, Gwon MJ, et al. Effect of local treatment in patients with oligo‐recurrence after surgery of distal bile duct cancer: A bi‐institutional study. Cancer Med. 2023;12:11274‐11283. doi: 10.1002/cam4.5836
So Jeong Yoon, Seung Soo Hong, Ho Kyoung Hwang and In Woong Han contributed equally to this work.
[Correction added on May 26, 2023 after first online publication. The Korean term has been removed from page 8 in this version.]
Contributor Information
Ho Kyoung Hwang, Email: drhhk@yuhs.ac.
In Woong Han, Email: cardioman76@gmail.com.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
REFERENCES
- 1. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512‐522. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Kwon HJ, Kim SG, Chun JM, Lee WK, Hwang YJ. Prognostic factors in patients with middle and distal bile duct cancers. World J Gastroenterol. 2014;20:6658‐6665. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Zhou Y, Liu S, Wu L, Wan T. Survival after surgical resection of distal cholangiocarcinoma: a systematic review and meta‐analysis of prognostic factors. Asian J Surg. 2017;40:129‐138. [DOI] [PubMed] [Google Scholar]
- 4. Komaya K, Ebata T, Shirai K, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017;104:426‐433. [DOI] [PubMed] [Google Scholar]
- 5. Singal AG, Rakoski MO, Salgia R, et al. The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care Centre. Aliment Pharmacol Ther. 2010;31:625‐633. [DOI] [PubMed] [Google Scholar]
- 6. Song SC, Heo JS, Choi DW, Choi SH, Kim WS, Kim MJ. Survival benefits of surgical resection in recurrent cholangiocarcinoma. J Korean Surg Soc. 2011;81:187‐194. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Niibe Y, Hayakawa K. Oligometastases and oligo‐recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010;40:107‐111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Lee JG, Lee SH, Lim JH, Park JS, Yoon DS, Kim KS. Is Pancreaticoduodenectomy feasible for recurrent remnant bile duct cancer following bile duct segmental resection? J Gastrointest Surg. 2015;19:2138‐2145. [DOI] [PubMed] [Google Scholar]
- 9. Yoon YS, Kim SW, Jang JY, Park YH. Curative reoperation for recurrent cancer of the extrahepatic bile duct: report of two cases. Hepatogastroenterology. 2005;52:381‐384. [PubMed] [Google Scholar]
- 10. Takahashi Y, Ebata T, Yokoyama Y, et al. Surgery for recurrent biliary tract cancer: a single‐center experience with 74 consecutive resections. Ann Surg. 2015;262:121‐129. [DOI] [PubMed] [Google Scholar]
- 11. Motoyama H, Kobayashi A, Yokoyama T, et al. Survival benefits of surgical resection in patients with recurrent biliary tract carcinoma. World J Surg. 2017;41:2817‐2829. [DOI] [PubMed] [Google Scholar]
- 12. Zhang W, Zhou H, Wang Y, et al. Systemic treatment of advanced or recurrent biliary tract cancer. Biosci Trends. 2020;14:328‐341. [DOI] [PubMed] [Google Scholar]
- 13. Hang H, Jeong S, Sha M, et al. Cholangiocarcinoma: anatomical location‐dependent clinical, prognostic, and genetic disparities. Ann Transl Med. 2019;7:744. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Strobel O, Hartwig W, Hackert T, et al. Re‐resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol. 2013;20:964‐972. [DOI] [PubMed] [Google Scholar]
- 15. Serafini S, Sperti C, Friziero A, et al. Systematic review and meta‐analysis of surgical treatment for isolated local recurrence of pancreatic cancer. Cancers (Basel). 2021;13:1277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Thomas RM, Truty MJ, Nogueras‐Gonzalez GM, et al. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012;16:1696‐1704. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Jang JY, Kim SW, Park DJ, et al. Actual long‐term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg. 2005;241:77‐84. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Kawai M, Tani M, Kobayashi Y, et al. The ratio between metastatic and examined lymph nodes is an independent prognostic factor for patients with resectable middle and distal bile duct carcinoma. Am J Surg. 2010;199:447‐452. [DOI] [PubMed] [Google Scholar]
- 19. Wu R, Zhang G, Feng J, Zhang L, Yang Z. Proposal of the optimal numbers of examined and positive lymph nodes to the 8th edition of American Joint Committee on Cancer (AJCC) staging for 758 patients with distal cholangiocarcinoma. PLoS One. 2020;15:e0234464. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Conci S, Campagnaro T, Danese E, et al. Role of inflammatory and immune‐nutritional prognostic markers in patients undergoing surgical resection for biliary tract cancers. Cancers (Basel). 2021;13:3594. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24‐37. [DOI] [PubMed] [Google Scholar]
- 22. Huz JI, Melis M, Sarpel U. Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response. HPB (Oxford). 2012;14:500‐505. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Kitano Y, Yamashita YI, Yamamura K, et al. Effects of preoperative neutrophil‐to‐lymphocyte and platelet‐to‐lymphocyte ratios on survival in patients with extrahepatic cholangiocarcinoma. Anticancer Res. 2017;37:3229‐3237. [DOI] [PubMed] [Google Scholar]
- 24. Ito Y, Abe Y, Egawa T, Kitago M, Itano O, Kitagawa Y. Predictive factors of early recurrence in patients with distal cholangiocarcinoma after pancreaticoduodenectomy. Gastroenterol Res Pract. 2018;2018:6431254‐6431257. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Akita M, Ajiki T, Ueno K, et al. Predictors of postoperative early recurrence of extrahepatic bile duct cancer. Surg Today. 2020;50:344‐351. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.